eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.
eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 25, 2017 | Grant | €1M | 1 | The Institute for the Promotion of Innovation by Science and Technology in Flanders | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 16, 2013
Armory Technologies, Inc.
|
Seed | $600K | Bitcoin | — |
Jan 7, 2013
BitPay
|
Seed | $510K | Bitcoin | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
The Institute for the Promotion of Innovation by Science and Technology in Flanders | Yes | Grant |